{"log_id": 7777489810091295559, "direction": 0, "words_result_num": 29, "words_result": [{"probability": {"variance": 1e-06, "average": 0.999083, "min": 0.994952}, "location": {"width": 715, "top": 253, "height": 31, "left": 247}, "words": "拉帕替尼禁用于对本品任何一种成分过敏的患者(参见【不良反应】)"}, {"probability": {"variance": 2e-06, "average": 0.999231, "min": 0.996096}, "location": {"width": 146, "top": 329, "height": 31, "left": 212}, "words": "【注意事项】"}, {"probability": {"variance": 3e-06, "average": 0.998538, "min": 0.994912}, "location": {"width": 208, "top": 375, "height": 27, "left": 201}, "words": "1左室射血分数降低"}, {"probability": {"variance": 3e-06, "average": 0.998746, "min": 0.992412}, "location": {"width": 835, "top": 429, "height": 32, "left": 247}, "words": "本品治疗期间曾有左室射血分数(LVEF)降低的报告(参见【不良反应】)。临"}, {"probability": {"variance": 4.8e-05, "average": 0.996621, "min": 0.962598}, "location": {"width": 880, "top": 476, "height": 30, "left": 203}, "words": "床试验中,大多数(>57%)LVEF降低发生在治疗的最初12周内,但长期暴露的数据"}, {"probability": {"variance": 2.2e-05, "average": 0.998034, "min": 0.975748}, "location": {"width": 878, "top": 520, "height": 34, "left": 202}, "words": "有限。如患者有左室功能受损的情况,应当慎用本品治疗。所有患者在开始使用本品"}, {"probability": {"variance": 1e-05, "average": 0.998669, "min": 0.984382}, "location": {"width": 881, "top": 567, "height": 32, "left": 203}, "words": "治疗之前都应先评估LVEF,并确定基线LVEF在所属医疗机构的正常值范围内。在使用"}, {"probability": {"variance": 9.8e-05, "average": 0.99632, "min": 0.941082}, "location": {"width": 738, "top": 613, "height": 32, "left": 203}, "words": "本品治疗期间,应继续监测LVEF,以确保LVEF的下降在可接受的范围内"}, {"probability": {"variance": 0.010978, "average": 0.570142, "min": 0.465364}, "location": {"width": 151, "top": 651, "height": 64, "left": 863}, "words": "价理"}, {"probability": {"variance": 0, "average": 0.998852, "min": 0.998796}, "location": {"width": 92, "top": 715, "height": 28, "left": 201}, "words": "2肝毒性"}, {"probability": {"variance": 6.2e-05, "average": 0.996268, "min": 0.955789}, "location": {"width": 834, "top": 769, "height": 31, "left": 249}, "words": "在本品的临床试验(<1%的患者)和上市后监测中观察到肝毒性(ALT或AST大于"}, {"probability": {"variance": 0.000327, "average": 0.995604, "min": 0.896538}, "location": {"width": 878, "top": 816, "height": 29, "left": 204}, "words": "正常范围上限的3倍,并且总胆红素大于正常范围上限的1.5倍)有患者出现严重肝"}, {"probability": {"variance": 0, "average": 0.999773, "min": 0.998947}, "location": {"width": 881, "top": 861, "height": 30, "left": 203}, "words": "毒性甚至死亡的报告,但这些情况与本品的关系尚不明确。肝毒性可能发生于治疗开"}, {"probability": {"variance": 6e-06, "average": 0.998898, "min": 0.986019}, "location": {"width": 880, "top": 908, "height": 28, "left": 203}, "words": "始的数天后或几个月后。患者在治疗前应检查肝功能,在治疗期间每隔4~6周监测肝"}, {"probability": {"variance": 4e-06, "average": 0.999045, "min": 0.989629}, "location": {"width": 882, "top": 953, "height": 29, "left": 202}, "words": "功能(转氨酶、胆红素和碱性磷酸酶),并根据临床需要随时进行检查。如果出现严"}, {"probability": {"variance": 0, "average": 0.999646, "min": 0.997382}, "location": {"width": 881, "top": 998, "height": 31, "left": 204}, "words": "重肝功能损害,需停止本品治疗,且病人不得再使用本品治疗(参见【不良反"}, {"probability": {"variance": 6e-06, "average": 0.997593, "min": 0.994123}, "location": {"width": 62, "top": 1047, "height": 26, "left": 204}, "words": "应】)"}, {"probability": {"variance": 0.004379, "average": 0.976863, "min": 0.77843}, "location": {"width": 212, "top": 1115, "height": 26, "left": 199}, "words": "3.重度肝损害的患者"}, {"probability": {"variance": 0.000495, "average": 0.956511, "min": 0.934256}, "location": {"width": 154, "top": 1077, "height": 62, "left": 901}, "words": " GUANGDONG PHARM"}, {"probability": {"variance": 0.041803, "average": 0.829262, "min": 0.47761}, "location": {"width": 201, "top": 1082, "height": 73, "left": 860}, "words": "图华润广含"}, {"probability": {"variance": 0.000687, "average": 0.993966, "min": 0.86301}, "location": {"width": 645, "top": 1170, "height": 30, "left": 249}, "words": "如果原有重度肝损害的患者需要使用本品,应当考虑减量。"}, {"probability": {"variance": 0.073832, "average": 0.776573, "min": 0.386471}, "location": {"width": 205, "top": 1135, "height": 80, "left": 882}, "words": "医药有严"}, {"probability": {"variance": 1e-06, "average": 0.999287, "min": 0.995523}, "location": {"width": 560, "top": 1217, "height": 28, "left": 202}, "words": "肝毒性的患者,应停用本品,且患者不得再用本品治疗"}, {"probability": {"variance": 0.035294, "average": 0.796792, "min": 0.509861}, "location": {"width": 132, "top": 1194, "height": 47, "left": 936}, "words": "米01“03"}, {"probability": {"variance": 0.019232, "average": 0.91941, "min": 0.679213}, "location": {"width": 70, "top": 1288, "height": 27, "left": 201}, "words": "4.腹泻"}, {"probability": {"variance": 4e-06, "average": 0.998987, "min": 0.98935}, "location": {"width": 835, "top": 1315, "height": 31, "left": 250}, "words": "本品治疗期间曾有腹泻(包括严重腹泻)的报告(参见【不良反应】)。早期发"}, {"probability": {"variance": 5e-06, "average": 0.998793, "min": 0.99064}, "location": {"width": 882, "top": 1360, "height": 31, "left": 203}, "words": "现和干预有利于达到最佳控制。医生应当指导患者如果发现排便有变化应当及时报"}, {"probability": {"variance": 4e-06, "average": 0.998871, "min": 0.989345}, "location": {"width": 883, "top": 1407, "height": 29, "left": 202}, "words": "告。建议在首次出现不成形便后立即用止泻剂治疗腹泻,如洛派丁胺。重度腹泻病例"}, {"probability": {"variance": 1e-06, "average": 0.999542, "min": 0.994585}, "location": {"width": 652, "top": 1452, "height": 31, "left": 203}, "words": "可能需要口服或静脉补充电解质和液体,并暂停或停止本品治疗"}], "language": 3}